Print Page
2601
Asthma Featured Biologics
Saturday, March 5, 2016: 2:00 PM-3:15 PM
Convention Center, Level Two, Room 502B
Oral Session
1.25 CME/CE
Primary Moderators:
Caroline C. Horner , MD FAAAAI
Christopher C. Randolph , MD FAAAAI
2:00 PM
282
Suppression of Lipid Mediators By the Humanized Anti-IgE Antibody Omalizumab in Aspirin-Exacerbated Respiratory Disease
Hiroaki Hayashi, MD
2:15 PM
283
Efficacy of Reslizumab with Asthma, Chronic Sinusitis with Nasal Polyps and Elevated Blood Eosinophils
Steven F. Weinstein, MD, FAAAAI
2:30 PM
284
Efficacy of Reslizumab in Older Patients (≥65 years) with Asthma and Elevated Blood Eosinophils: Results from a Pooled Analysis of Two Phase 3, Placebo-Controlled Trials
David I. Bernstein, MD FAAAAI
2:45 PM
285
Exploratory Analysis of the Roles of Multiple Biomarkers in Predicting Response to Omalizumab in Allergic Asthma
William W. Busse, MD FAAAAI
3:00 PM
286
Omalizumab Decreases Rates of Cold Symptoms in Inner-City Children with Allergic Asthma
Ann T. Esquivel, MD
See more of: Abstracts
<< Previous Session | Next Session >>